Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

INMBullishM&Anews

High materiality9/10

InMed Pharmaceuticals Announces Merger with Mentari Therapeutics

May 19, 2026, 10:26 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The merger provides a strong growth narrative, likely leading to an increase in INM's valuation. Historical examples of biotech mergers show substantial price gains post-announcement.

AI summary

What happened, with direct paths to the underlying reporting

InMed Pharmaceuticals has entered a merger agreement with Mentari Therapeutics, focusing on migraine therapies. The transaction will create a new entity with significant funding to advance drug development, likely enhancing INM's market position and valuation.

InMed announces merger with Mentari Therapeutics, enhancing migraine therapy potential.
Funding of $290 million secures operations through 2028 for combined entity.
Regulatory filings for two drug candidates expected by 2026-2027.
Merger approved by both companies; will close in H2 2026.
Pre-merger shareholders own approximately 1.51% of combined company.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

InMed Pharmaceuticals Announces Merger with Mentari Therapeutics

Mentari's $200M private placement linked to InMed merger

InMed Pharmaceuticals Advances Oral Candidate For Alzheimer's Disease, Stock Surges On Tuesday